Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
September 18, 2012
Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility
Ryan T Bushey, Philip Lazarus
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
October 23, 2012
Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism
Ryan T Bushey, Douglas F Dluzen, Philip Lazarus
Plos One
|
June 16, 2021
Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis
Ryan T Bushey, Elizabeth B Gottlin, Michael J Campa, et al.
Cancer Immunology Research
|
July 29, 2015
Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy
Michael J Campa, Elizabeth B Gottlin, Ryan T Bushey, et al.
Pharmacogenetics and Genomics
|
December 18, 2010
Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis
Ryan T Bushey, Gang Chen, Andrea S Blevins-Primeau, et al.
Molecular Cancer Therapeutics
|
March 30, 2023
Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
Ryan T Bushey, Ruchi Saxena, Michael J Campa, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 9, 2014
Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p
Douglas F Dluzen, Dongxiao Sun, Anna C Salzberg, et al.
Cancer Biomarkers : Section a of Disease Markers
|
January 24, 2022
Prognostic significance of a complement factor H autoantibody in early stage NSCLC
Elizabeth B Gottlin, Michael J Campa, Rikesh Gandhi, et al.
Frontiers in Cell and Developmental Biology
|
February 23, 2024
Complement factor H: a novel innate immune checkpoint in cancer immunotherapy
Ruchi Saxena, Elizabeth B Gottlin, Michael J Campa, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 1, 2024
Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody
Ruchi Saxena, Ryan T Bushey, Michael J Campa, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
The Journal of Pharmacology and Experimental Therapeutics
|
September 18, 2012
Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility
Ryan T Bushey, Philip Lazarus
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
October 23, 2012
Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism
Ryan T Bushey, Douglas F Dluzen, Philip Lazarus
Plos One
|
June 16, 2021
Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis
Ryan T Bushey, Elizabeth B Gottlin, Michael J Campa, et al.
Cancer Immunology Research
|
July 29, 2015
Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy
Michael J Campa, Elizabeth B Gottlin, Ryan T Bushey, et al.
Pharmacogenetics and Genomics
|
December 18, 2010
Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis
Ryan T Bushey, Gang Chen, Andrea S Blevins-Primeau, et al.
Molecular Cancer Therapeutics
|
March 30, 2023
Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
Ryan T Bushey, Ruchi Saxena, Michael J Campa, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 9, 2014
Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p
Douglas F Dluzen, Dongxiao Sun, Anna C Salzberg, et al.
Cancer Biomarkers : Section a of Disease Markers
|
January 24, 2022
Prognostic significance of a complement factor H autoantibody in early stage NSCLC
Elizabeth B Gottlin, Michael J Campa, Rikesh Gandhi, et al.
Frontiers in Cell and Developmental Biology
|
February 23, 2024
Complement factor H: a novel innate immune checkpoint in cancer immunotherapy
Ruchi Saxena, Elizabeth B Gottlin, Michael J Campa, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 1, 2024
Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody
Ruchi Saxena, Ryan T Bushey, Michael J Campa, et al.
Page
of 2